Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

TP53 mutation is an independent marker of poor prognosis in patients with diffuse large B-cell lymphoma (DLBCL) treated with cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone (CHOP) therapy. However, its prognostic value in the rituximab immunochemotherapy era remains undefined. In...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Xu-Monette, Zijun Y., Wu, Lin, Visco, Carlo, Tai, Yu Chuan, Tzankov, Alexander, Liu, Wei-min, Montes-Moreno, Santiago, Dybkær, Karen, Chiu, April, Orazi, Attilio, Zu, Youli, Bhagat, Govind, Richards, Kristy L., Hsi, Eric D., Zhao, X. Frank, Choi, William W. L., Zhao, Xiaoying, van Krieken, J. Han, Huang, Qin, Huh, Jooryung, Ai, Weiyun, Ponzoni, Maurilio, Ferreri, Andrés J. M., Zhou, Fan, Kahl, Brad S., Winter, Jane N., Xu, Wei, Li, Jianyong, Go, Ronald S., Li, Yong, Piris, Miguel A., Møller, Michael B., Miranda, Roberto N., Abruzzo, Lynne V., Medeiros, L. Jeffrey, Young, Ken H.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2012
Materias:
Clinical Trials and Observations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3496956/
https://ncbi.nlm.nih.gov/pubmed/22955915
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-05-433334
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares